Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aditxt, Inc.

< Previous 1 2 Next >
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF TSX:APLI
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.